{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"12"}],"units":"Participants"}],"description":"Number of patients surviving overall post-transplant","groups":[{"description":"NONMYELOABLATIVE PREPARATIVE REGIMEN: Patients receive fludarabine phosphate intravenously (IV) on days -4 to -2 (except for patients who had prior autologous HCT or equivalent high-dose therapy without HCT) and undergo low-dose total body irradiation (TBI) on day 0.\n\nTRANSPLANT: Patients undergo donor PBSC transplant on day 0.\n\nPOST-GRAFTING IMMUNOSUPPRESSION: Patients receive CSP PO twice daily (BID) on days -3 to 56 with taper to day 180. Patients also receive mycophenolate mofetil (MMF) PO BID or IV every 12 hours on days 0-27.","id":"OG000","title":"Primary - Reg A (Flu/TBI)"},{"description":"NONMYELOABLATIVE PREPARATIVE REGIMEN: Patients will undergo low-dose total body irradiation (TBI) on day 0.\n\nTRANSPLANT: Patients undergo donor PBSC transplant on day 0.\n\nPOST-GRAFTING IMMUNOSUPPRESSION: Patients receive CSP PO twice daily (BID) on days -3 to 56 with taper to day 180. Patients also receive mycophenolate mofetil (MMF) PO BID or IV every 12 hours on days 0-27.","id":"OG001","title":"Primary - Reg B (TBI Alone)"},{"description":"NONMYELOABLATIVE PREPARATIVE REGIMEN: The preparative regimen and immunosuppression after transplant will be according to respective protocol or treatment plan.\n\nPOST-GRAFTING IMMUNOSUPPRESSION: Patients receive CSP PO twice daily (BID) on days -3 to 56 with taper to day 180. Patients also receive mycophenolate mofetil (MMF) PO BID or IV every 12 hours on days 0-27.","id":"OG002","title":"Adjunct"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"One subject on Reg A aborted transplant during conditioning due to donor related medical issue and subsequently went on to transplant on a different study. This subject was counted towards accrual but not evaluated with respect to outcome measures.","reportingStatus":"POSTED","timeFrame":"1 Year post-transplant","title":"Number of Patients Surviving Overall","type":"SECONDARY","unitOfMeasure":"Participants"}